Allan Olson

14.5k total citations · 5 hit papers
74 papers, 11.0k citations indexed

About

Allan Olson is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Allan Olson has authored 74 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 29 papers in Epidemiology and 22 papers in Surgery. Recurrent topics in Allan Olson's work include Inflammatory Bowel Disease (39 papers), Microscopic Colitis (25 papers) and Sphingolipid Metabolism and Signaling (9 papers). Allan Olson is often cited by papers focused on Inflammatory Bowel Disease (39 papers), Microscopic Colitis (25 papers) and Sphingolipid Metabolism and Signaling (9 papers). Allan Olson collaborates with scholars based in United States, Canada and Belgium. Allan Olson's co-authors include Paul Rutgeerts, Brian G. Feagan, Gary R. Lichtenstein, Jean‐Frédéric Colombel, Daniel Rachmilewitz, Stephen B. Hanauer, Lloyd Mayer, Douglas C. Wolf, Weihang Bao and Stefan Schreiber and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Allan Olson

74 papers receiving 10.6k citations

Hit Papers

Maintenance infliximab for Crohn's disease: the ACCENT I ... 2002 2026 2010 2018 2002 2005 2004 2006 2016 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    2002 3.2k citations Stephen B. Hanauer, Brian G. Feagan et al. profile →
  2. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
    2005 2.9k citations Paul Rutgeerts, William J. Sandborn et al. profile →
  3. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
    2004 737 citations Paul Rutgeerts, Brian G. Feagan et al. Gastroenterology profile →
  4. Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children
    2006 662 citations Jeffrey S. Hyams, Wallace Crandall et al. Gastroenterology profile →
  5. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
    2016 360 citations William J. Sandborn, Brian G. Feagan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Allan Olson United States 28 8.9k 6.9k 3.0k 2.5k 908 74 11.0k
Jewel Johanns United States 32 8.6k 1.0× 6.5k 0.9× 3.4k 1.1× 2.3k 0.9× 862 0.9× 119 10.4k
Maja Noman Belgium 37 7.1k 0.8× 5.6k 0.8× 2.9k 0.9× 2.2k 0.9× 657 0.7× 100 9.8k
Douglas C. Wolf United States 35 10.8k 1.2× 8.4k 1.2× 3.6k 1.2× 3.6k 1.4× 1.2k 1.3× 114 13.3k
Filip Baert Belgium 42 8.6k 1.0× 6.6k 1.0× 2.8k 0.9× 3.1k 1.2× 580 0.6× 137 11.0k
Robert H. Diamond United States 30 5.7k 0.6× 5.0k 0.7× 1.9k 0.6× 2.0k 0.8× 476 0.5× 56 8.2k
Simon Lichtiger United States 25 5.3k 0.6× 4.1k 0.6× 1.4k 0.5× 2.0k 0.8× 381 0.4× 64 6.9k
Niels Vande Casteele United States 43 5.1k 0.6× 3.6k 0.5× 2.9k 0.9× 1.2k 0.5× 389 0.4× 158 6.8k
Suzanne Travers United States 9 5.0k 0.6× 3.8k 0.5× 1.6k 0.5× 1.6k 0.6× 418 0.5× 14 6.0k
Robert Löfberg Sweden 49 5.7k 0.6× 4.4k 0.6× 945 0.3× 2.6k 1.0× 313 0.3× 140 8.0k
Suk‐Kyun Yang South Korea 47 4.5k 0.5× 3.7k 0.5× 1.0k 0.3× 3.7k 1.5× 232 0.3× 384 9.5k

Countries citing papers authored by Allan Olson

Since Specialization
Citations

This map shows the geographic impact of Allan Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan Olson more than expected).

Fields of papers citing papers by Allan Olson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allan Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan Olson. The network helps show where Allan Olson may publish in the future.

Co-authorship network of co-authors of Allan Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Allan Olson. A scholar is included among the top collaborators of Allan Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan Olson. Allan Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Feagan, Brian G., William J. Sandborn, Silvio Danese, et al.. (2020). Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. ˜The œLancet. Gastroenterology & hepatology. 5(9). 819–828. 107 indexed citations
2.
Jairath, Vipul, Laurent Peyrin‐Biroulet, Guangyong Zou, et al.. (2018). Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 68(7). 1162–1168. 39 indexed citations
3.
Cohen, Jeffrey A., Douglas L. Arnold, Cristoforo Comi, et al.. (2016). Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. 15(4). 373–381. 144 indexed citations
4.
Comı, Gıancarlo, Jeffrey A. Cohen, Douglas L. Arnold, et al.. (2015). Efficacy Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Adults with Relapsing Multiple Sclerosis (P7.198). Neurology. 84(14_supplement). 5 indexed citations
5.
6.
Hartung, Jeffrey, Allan Olson, Robert Peach, et al.. (2014). Absence Of A Relevant Effect On Cardiac Repolarization In A QT/QTc (TQT) Study of RPC1063, A Novel, Selective S1P1 Receptor Agonist, In Healthy Adult Volunteers (P2.229). Neurology. 82(10_supplement). 1 indexed citations
7.
Gheorghiade, Mihai, Stephen J. Greene, Piotr Ponikowski, et al.. (2013). Haemodynamic Effects, Safety, and Pharmacokinetics of Human Stresscopin in Heart Failure with Reduced Ejection Fraction. European Journal of Heart Failure. 15(6). 679–689. 29 indexed citations
8.
Olson, Allan, Jeffrey Hartung, Gregg Timony, et al.. (2013). Safety and Tolerability of Orally Administered RPC1063, a Novel S1P1 Receptor Modulator, in Healthy Adult Volunteers, Results of a Phase 1 Study (P01.178). Neurology. 80(7_supplement). 5 indexed citations
9.
Sandborn, William J., Paul Rutgeerts, Brian G. Feagan, et al.. (2009). Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. Gastroenterology. 137(4). 1250–1260. 356 indexed citations
10.
Hyams, Jeffrey S., Wallace Crandall, Subra Kugathasan, et al.. (2006). Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children. Gastroenterology. 132(3). 863–873. 662 indexed citations breakdown →
11.
Geboes, Karel, Paul Rutgeerts, Ghislain Opdenakker, et al.. (2005). Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Current Medical Research and Opinion. 21(11). 1741–1754. 93 indexed citations
12.
Feagan, Brian G., Mohan Bala, Songkai Yan, Allan Olson, & Stephen B. Hanauer. (2005). Unemployment and Disability in Patients With Moderately to Severely Active Crohn's Disease. Journal of Clinical Gastroenterology. 39(5). 390–395. 100 indexed citations
13.
Mascheretti, Silvia, Jochen Hampe, Peter J.P. Croucher, et al.. (2002). Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials.. Pharmacogenetics. 12(7). 509–515. 118 indexed citations
14.
Olson, Allan, et al.. (1997). Cost‐Benefit Analysis of Interferon Therapy in Children with Chronic Active Hepatitis B. Journal of Pediatric Gastroenterology and Nutrition. 24(1). 25–32. 2 indexed citations
15.
Deutsch, David & Allan Olson. (1997). Colonoscopy or Sigmoidoscopy as the Initial Evaluation of Pediatric Patients with Colitis: A Survey of Physician Behavior and a Cost Analysis. Journal of Pediatric Gastroenterology and Nutrition. 25(1). 26–31. 27 indexed citations
16.
Olson, Allan, et al.. (1997). Cost-Benefit Analysis of Interferon Therapy in Children with Chronic Active Hepatitis B. Journal of Pediatric Gastroenterology and Nutrition. 24(1). 25–32. 19 indexed citations
17.
Hillemeier, A. Craig, et al.. (1996). Lack of Evidence for Seasonal Variation in Extrahepatic Biliary Atresia During Infancy. Journal of Clinical Gastroenterology. 22(4). 292–294. 17 indexed citations
18.
Olson, Allan, et al.. (1995). Antiserum to Tumor Necrosis Factor and Failure to Prevent Murine Colitis. Journal of Pediatric Gastroenterology and Nutrition. 21(4). 410–418. 37 indexed citations
19.
Olson, Allan, et al.. (1995). Antiserum to Tumor Necrosis Factor and Failure to Prevent Murine Colitis. Journal of Pediatric Gastroenterology and Nutrition. 21(4). 410–418. 4 indexed citations
20.
Olson, Allan, Theodore J. Pysher, & Robert S. Bienkowski. (1991). Organization of intestinal epithelial cells into multicellular structures requires laminin and functional actin microfilaments. Experimental Cell Research. 192(2). 543–549. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jewel Johanns Breakdown of academic impact, for papers by Maja Noman Breakdown of academic impact, for papers by Douglas C. Wolf Breakdown of academic impact, for papers by Filip Baert Breakdown of academic impact, for papers by Robert H. Diamond Breakdown of academic impact, for papers by Simon Lichtiger Breakdown of academic impact, for papers by Niels Vande Casteele Breakdown of academic impact, for papers by Suzanne Travers Breakdown of academic impact, for papers by Robert Löfberg Breakdown of academic impact, for papers by Suk‐Kyun Yang
Rankless by CCL
2026